

## Disclosure of total number of voting rights and number of shares in the capital as of June 30<sup>th</sup>, 2024

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

Total number of shares	<b>18,418,233</b>
Number of real voting rights* (excluding treasury shares**)	<b>18,358,898</b>
Theoretical number of voting rights* (including treasury shares**)	<b>18,395,033</b>

(\*) Class E preference shares are non-voting

(\*\*) pursuant to article 223-11 of the AMF’s General Regulations



**About Median Technologies:** Pioneering innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit [www.mediantechnologies.com](http://www.mediantechnologies.com).

### Contacts

<b>Median Technologies</b> Emmanuelle Leygues Head of Corporate Marketing & Financial Communications +33 6 10 93 58 88 <a href="mailto:emmanuelle.leygues@mediantechnologies.com">emmanuelle.leygues@mediantechnologies.com</a>	<b>Press - ALIZE RP</b> Caroline Carmagnol +33 6 64 18 99 59 <a href="mailto:median@alizerp.com">median@alizerp.com</a>	<b>Investors - ACTIFIN</b> Ghislaine Gasparetto +33 6 21 10 49 24 <a href="mailto:ghislaine.gasparetto@seitosei-actifin.com">ghislaine.gasparetto@seitosei-actifin.com</a>
---	--	---